Three Things to Know About Our New Vice President of Communications & Marketing

At Medicines360, our culture is built on a shared passion for advancing women’s health, driven by a team of experts who know the science, and trailblazers who shape new systems and construct solutions for the challenges women face every day.

When Stacey Manley previously worked at Medicines360, it marked his first foray into social impact work after nearly two decades in brand advertising. This shift in trajectory later took him to positions in private and community philanthropy, where his work focused on developing communications to help scale social change solutions. As our new Vice President of Communications & Marketing, he brings to Medicines360 deep experience in strategic communications, brand identity, organizational development, and social impact analysis to help advance our efforts to close critical gaps in women’s healthcare.

We recently checked in with Stacey to welcome him back, chat about what he’s been up to, and get his perspective on the future of communications for the organization.

Welcome back, Stacey! For those who haven’t had a chance to work with you yet, can you explain what made you choose this opportunity to return to Medicines360?

Having been back in the saddle for a few months now, returning to Medicines360 feels a lot like a homecoming. It is a welcomed chance to partner with people who practice what it means to be mission‐ driven. Demonstrating fidelity to purpose is at the heart of our organizational decision‐making, and this quality is consistent with the philanthropic institutions where I most recently worked. In my estimation, this kind of focus and commitment is necessary to facilitate meaningful societal change. Over the years, Medicines360 has made tremendous progress in helping women access affordable medicines. I’m incredibly excited to help tell our larger story in ways that will inspire additional entrants and catalyze more investment in the space. More than ever, we must make it easier for nonprofit pharma organizations like ours to fill the gaps and increase access to potentially life‐changing medicines.

How do your background and previous experience position you to make an impact for women through your work at Medicines360?

When I joined Medicines360 nearly a decade ago, it represented my first foray into social impact work after almost two decades in the private sector and an inflection point in my career as a brand communications professional. Until then, I had built a skill set rooted in affecting consumer buying behaviors but quickly realized that impacting attitudes was also the precursor to shifting narratives that allow us to take on the most pressing societal challenges. This discovery led me to explore more communications roles in social impact, where I developed strategies and campaigns that challenged outmoded ways of thinking about longstanding social disparities. I’m excited to bring this perspective to Medicines360 and focus on how we can leverage our reputational identity as a strategic, organizational asset.

Why is Medicines360’s mission and work important in the current environment?

Despite women’s social, economic, and political achievements, there are still significant gaps in access to healthcare. This is largely a function of a system that has not prioritized developing structures or services necessary to meet the basic health and life needs of all. While Medicines360’s core expertise lies in product development, the vision to which we aspire includes helping to create the conditions necessary for change to happen. And the timing of our work could not be better. As our country continues examining inequities across society, more and more there is a realization that addressing structural issues requires imagining new models and systems that will enable each person to reach their fullest potential. And getting access to needed medicines is central to that objective.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.